Crinetics Pharmaceuticals: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q4 earnings with an EPS of $-0.9, missing estimates by -5.0% and showing a revenue decrease of $709 thousand from the previous year. This follows a pattern of missed EPS estimates in previous quarters, with a notable 4.0% share price drop after last quarter's earnings miss.
February 28, 2024 | 9:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Crinetics Pharmaceuticals reported a Q4 EPS of $-0.9, missing estimates by -5.0%, with a year-over-year revenue decrease. This continues a trend of missed EPS estimates.
Given the reported earnings miss and the historical context of share price dropping after previous earnings misses, it's likely that CRNX's share price will experience short-term negative pressure. The pattern of missing EPS estimates and the subsequent market reactions suggest a bearish outlook in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100